Brokerages Expect Regenxbio Inc (NASDAQ:RGNX) Will Announce Quarterly Sales of $6.26 Million

Wall Street brokerages predict that Regenxbio Inc (NASDAQ:RGNX) will announce sales of $6.26 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Regenxbio’s earnings, with estimates ranging from $5.31 million to $7.20 million. Regenxbio posted sales of $5.31 million in the same quarter last year, which indicates a positive year over year growth rate of 17.9%. The business is scheduled to report its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Regenxbio will report full-year sales of $47.55 million for the current financial year, with estimates ranging from $13.26 million to $76.35 million. For the next fiscal year, analysts expect that the company will report sales of $193.82 million, with estimates ranging from $157.26 million to $286.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Regenxbio.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.46. Regenxbio had a negative return on equity of 15.39% and a negative net margin of 88.57%. The firm had revenue of $7.88 million during the quarter, compared to analyst estimates of $5.45 million. During the same quarter in the previous year, the business earned $0.30 earnings per share. Regenxbio’s quarterly revenue was down 80.3% on a year-over-year basis.



RGNX has been the topic of several research reports. Zacks Investment Research upgraded Regenxbio from a “sell” rating to a “hold” rating in a research note on Thursday, July 25th. Raymond James started coverage on shares of Regenxbio in a research note on Thursday, June 13th. They issued an “outperform” rating for the company. Svb Leerink upgraded shares of Regenxbio from an “underperform” rating to a “market perform” rating and dropped their target price for the stock from $38.00 to $37.00 in a report on Tuesday, August 20th. Morgan Stanley set a $84.00 target price on shares of Regenxbio and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, Chardan Capital set a $150.00 target price on shares of Regenxbio and gave the company a “buy” rating in a research report on Wednesday, September 4th. One analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $79.56.

Shares of RGNX stock traded up $1.43 during mid-day trading on Friday, hitting $37.38. The stock had a trading volume of 34,987 shares, compared to its average volume of 454,207. Regenxbio has a 12-month low of $30.38 and a 12-month high of $83.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.58 and a quick ratio of 14.58. The firm’s 50-day moving average is $38.58 and its two-hundred day moving average is $47.95. The firm has a market capitalization of $1.32 billion, a P/E ratio of 15.72 and a beta of 0.82.

In other news, SVP Patrick J. Christmas sold 5,000 shares of Regenxbio stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $52.99, for a total value of $264,950.00. Following the transaction, the senior vice president now owns 8,006 shares of the company’s stock, valued at approximately $424,237.94. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $49.49, for a total transaction of $742,350.00. Following the transaction, the insider now owns 261,000 shares of the company’s stock, valued at approximately $12,916,890. The disclosure for this sale can be found here. Insiders have sold a total of 55,000 shares of company stock valued at $2,608,800 over the last 90 days. 13.80% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Oregon Public Employees Retirement Fund boosted its holdings in shares of Regenxbio by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 11,660 shares of the biotechnology company’s stock valued at $668,000 after acquiring an additional 211 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Regenxbio by 9.5% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,594 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 225 shares during the period. Berman Capital Advisors LLC lifted its stake in shares of Regenxbio by 41.6% in the 2nd quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 333 shares during the period. Mason Street Advisors LLC increased its stake in shares of Regenxbio by 5.1% during the first quarter. Mason Street Advisors LLC now owns 9,825 shares of the biotechnology company’s stock valued at $563,000 after acquiring an additional 476 shares during the period. Finally, Aperio Group LLC increased its stake in shares of Regenxbio by 10.3% during the second quarter. Aperio Group LLC now owns 5,204 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 486 shares during the period. Institutional investors own 79.43% of the company’s stock.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Further Reading: Sell-Side Analysts

Get a free copy of the Zacks research report on Regenxbio (RGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.